Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editing Technologies and Applications Session at the 25th Annual Meeting of the American Society of Gene and […]
ALDEVRON LICENSES THE MANUFACTURING OF A TYPE-V CRISPR NUCLEASE FROM INSCRIPTA
FARGO, N.D. , May 16, 2022 /PRNewswire/ —Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron […]
Foundation Fighting Blindness to Host VISIONS 2022 Conference
COLUMBIA, Md., May 12, 2022 /PRNewswire/ — The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, will host its VISIONS 2022 national conference at Disney’s Coronado Springs Resort on June 17–18, 2022. This one-of-a-kind biennial event will provide attendees the opportunity to hear about exciting advancements […]
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on […]
The Global Regenerative Medicines Market is expected to grow by $ 28.67 bn during 2022-2026, accelerating at a CAGR of 14.57% during the forecast period
New York, May 09, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Regenerative Medicines Market 2022-2026” – https://www.reportlinker.com/p06275855/?utm_source=GNW57% during the forecast period. Our report on the regenerative medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The […]
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
WORCESTER, Mass., May 03, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on treatment with the same lentiviral vector […]
Vitti Labs Announces FDA Approval of Phase II IND Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Pulmonary Fibrosis Secondary to Novel Corona Virus Infection (COVID-19)
LIBERTY, Mo., May 2, 2022 /PRNewswire/ — Vitti Labs, an AATB Accredited Tissue Bank focused on life Science Research, development, and manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved their Investigational New Drug Application (IND) to move forward with Phase II Outpatient Clinical Trial using a combination of Umbilical Cord […]
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting in Uniondale, NY on April 29th – 30th, 2022 for the Company’s lead clinical candidate BRTX-100®, an autologous bone […]
FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial
AUSTIN, Texas, April 26, 2022 /PRNewswire/ — Direct Biologics, a regenerative biotechnology company with a groundbreaking extracellular vesicle (EV) platform technology, announced today that the FDA has approved the company to proceed with its Phase 3 clinical trial using its investigational EV drug, ExoFlo, to treat Acute Respiratory Distress Syndrome (ARDS) due to Covid-19. Direct […]
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC). The […]